A GPO Update
Generic Enoxaparin Launch
As a generic version of Lovenox® has been introduced into the U.S. market over the last few weeks, HealthTrust Pharmacy Group has received many questions from its membership regarding enoxaparin, the generic launch, and the future of this class of pharmaceuticals. Currently, HealthTrust has a sole award with Sanofi-Aventis for brand name Lovenox®. Sanofi-Aventis recently brought additional value to HealthTrust's existing contract for Lovenox®, thus bringing additional value to the membership. This change in contract terms and value has been reflected in a previous Pharmacy Response and on CatScanRX.
As part of our value service to our members, we will continue to monitor the enoxaparin market and stay in contact with our vendors to ensure that our members maintain maximum value in this space.
HealthTrust Pharmacy Team has developed a list of frequently asked questions to assist members with understanding what goes into gaining approval of a generic version of enoxaparin, and how the generic presentations will compare to each other and to Lovenox®. Members should review this document and initiate conversations with nursing, physicians, and other healthcare providers regarding generic enoxaparin as the market and value offerings continue to develop.
The preceding was from an e-mail I received at a hospital who belongs to the GPO Healthtrust (HPG) with parts marked "Confidential" removed.
Can another Healthtrust member on this board corroborate it as I don't have a link to share that isn't password protected? Thanks--Bill.
AI
Market Data 
Markets 
